CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Aug 28, 2018--Nuvera Life Science Consulting, an expert partner in developing patient-centric experience strategies for specialty therapeutics, will share key factors for manufacturers of CAR-TCR therapies to consider as they prepare for commercialization at the fourth annual CAR-TCR Summit in Boston Sept. 4-7.

In a presentation titled “ Ensuring an Exceptional Support Experience from Clinical Trials to Commercialization,” Nuvera will outline how to leverage experience gained during the clinical trials phase of CAR-TCR therapies to enhance commercialization success. Drawing from 12 years of expertise delivering leading patient-centered solutions and 3 years of in-depth work in the emerging CAR-TCR space, Nuvera will highlight the issues manufacturers face when developing the support infrastructure for their clinical trial programs.

“The ‘heritage’ created during the clinical trial for both the manufacturer and their clinical trial site is significantly different for CAR-TCR versus other specialty therapies,” said Nuvera Principal Greg Christianson. “Understanding how to leverage the development of this heritage is paramount to a successful launch upon approval. We’ve worked intimately with existing CAR-TCR therapies to learn the challenges involved and develop seamless patient/healthcare provider (HCP) user experiences through a range of strategic and tactical approaches, including our Treatment Experience Blueprint©.”

Using this blueprint, Nuvera mapped out the end-to-end treatment journey for CAR-TCR and identified the key pain points and “moments that matter” for patients and HCPs, which informed the development of nontraditional support activities.

“I’m very excited to share our learnings at the CAR-TCR Summit to help design successful support programs, which will enhance the future utilization of this amazing technology for patients who often have no remaining treatment options,” Christianson said.

About Nuvera Life Science Consulting

Nuvera Life Science Consulting helps the world’s leading pharmaceutical and biotech companies deliver impactful patient and HCP support experiences for specialty and rare-disease therapies. Nuvera excels at uncovering patient/HCP needs, and crafting and helping execute seamless treatment experiences that enhance patients’ ability to obtain, start, and stay on therapies. Over the last 12 years, Nuvera has partnered with a multitude of companies to implement solutions across 24 specialty therapeutic areas, earning its client partners 10 U.S. and global excellence awards. To learn more, please visit nuveracg.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180828005097/en/

CONTACT: Nuvera Life Science Consulting

Patricia Candela, 973-600-9466

Executive Support

patricia.candela@nuveracg.com

nuveracg.com

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH

SOURCE: Nuvera Life Science Consulting

Copyright Business Wire 2018.

PUB: 08/28/2018 10:00 AM/DISC: 08/28/2018 10:01 AM

http://www.businesswire.com/news/home/20180828005097/en